DNLI
Denali Therapeutics Inc.
+0.23 (+1.15%)20.29USD385K成交股數3.2B市值–本益比(近四季)899.9股價營收比–營收年增(近四季)2026-11-05下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 3.6M | – | – | – | 0.00 | – | 0.00-100% | 0.00-100% | 0.00 | 0.00 | 1.3M | 294M |
| 營業成本 | 93K | – | – | – | 0.00 | – | – | – | – | – | – | – |
| 毛利 | 3.5M | – | – | – | 0.00 | – | – | – | – | – | – | – |
| 毛利率 | 97.4% | – | – | – | – | – | – | – | – | – | – | – |
| 研發費用 | 97.0M | 104M | 97.9M | 102M | 103M | 116M | 98.2M | 91.4M | 107M | 108M | 89.7M | 97.5M |
| 銷售管理費用 | 36.3M | 33.5M | 39.5M | 35.5M | 32.3M | 29.4M | 24.9M | 25.2M | 25.2M | 24.8M | 25.3M | 26.1M |
| 營業利益 | −131M-3% | −137M-6% | −137M+12% | −137M+18% | −135M+15% | −146M+10% | −123M+8% | −117M-168% | −118M | −133M | −114M | 170M |
| 營業利益率 | -3,622.1% | – | – | – | – | – | – | – | – | – | -8,981.5% | 58.0% |
| 稅後淨利 | −128M+3% | −128M-3% | −129M+20% | −127M+28% | −124M+22% | −133M+11% | −107M+8% | −99.0M-154% | −102M | −119M | −99.4M | 183M |
| 淨利率 | -3,539.2% | – | – | – | – | – | – | – | – | – | -7,841.6% | 62.3% |
| 稀釋 EPS | -0.68-6% | -0.69-12% | -0.73+16% | -0.74+25% | -0.72+6% | -0.78-7% | -0.63-13% | -0.59-145% | -0.68 | -0.84 | -0.72 | 1.30 |
| 稀釋股數 | 187M | 187M | 173M | 172M | 171M | 171M | 169M | 169M | 149M | 137M | 138M | 141M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 202M | 388M | 205M | 91.0M | 141M | 56.9M | 90.6M | 74.7M | 60.6M | 127M | 148M | 132M |
| 應收帳款 | 3.9M | – | 0.00 | – | – | – | – | – | – | – | – | – |
| 存貨 | 4.1M | – | 0.00 | – | – | – | – | – | – | – | – | – |
| 總資產 | 1.2B | 1.3B | 1.1B | 1.1B | 1.2B | 1.3B | 1.5B | 1.5B | 1.6B | 1.2B | 1.2B | 1.3B |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | 323M | 340M | 131M | 129M | 139M | 149M | 136M | 116M | 126M | 123M | 118M | 119M |
| 股東權益 | 835M | 926M | 1.0B | 926M | 1.0B | 1.1B | 1.3B | 1.4B | 1.5B | 1.0B | 1.1B | 1.2B |
| 負債比 | 27.9% | 26.8% | 11.5% | 12.3% | 11.9% | 11.7% | 9.3% | 7.7% | 7.9% | 10.7% | 9.6% | 9.1% |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −131M-0% | – | – | – | −131M | – | – | −114M | – | – | – |
| 資本支出 | – | 2.5M | – | – | – | 5.1M | – | – | 2.2M | – | – | – |
| 自由現金流 | – | −134M-2% | – | – | – | −137M | – | – | −116M | – | – | – |
| 折舊攤銷 | – | 2.8M | – | – | – | 2.3M | – | – | 2.2M | – | – | – |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | – | – | – | – | – | – | – | – | – | – | – |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
這家公司的 XBRL 沒有標分部、產品或地區營收。多半是單一業務,或只在 10-K 文字裡揭露。
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 0.00 | – | −513M | –% | -2.97 | −422M |
| FY2024 | 0.00 | -100.0% | −423M | –% | -2.57 | −364M |
| FY2023 | 331M | +214.6% | −145M | -43.9% | -1.06 | −371M |
| FY2022 | 105M | +115.9% | −326M | -310.3% | -2.60 | −263M |
| FY2021 | 48.7M | -85.5% | −291M | -597.2% | -2.39 | −220M |
| FY2020 | 336M | +1174.9% | 71.1M | 21.2% | 0.63 | 413M |
| FY2019 | 26.3M | -79.6% | −198M | -750.8% | -2.07 | −169M |
| FY2018 | 129M | – | −36.2M | -28.1% | -0.39 | 46.7M |